Haemonetics Corporation (HAE)
- Previous Close
83.62 - Open
84.20 - Bid 50.00 x 900
- Ask --
- Day's Range
83.68 - 85.84 - 52 Week Range
70.74 - 95.26 - Volume
225,362 - Avg. Volume
486,020 - Market Cap (intraday)
4.32B - Beta (5Y Monthly) 0.36
- PE Ratio (TTM)
34.58 - EPS (TTM)
2.46 - Earnings Date May 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
105.57
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
www.haemonetics.comRecent News: HAE
Performance Overview: HAE
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HAE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HAE
Valuation Measures
Market Cap
4.32B
Enterprise Value
5.00B
Trailing P/E
34.58
Forward P/E
19.80
PEG Ratio (5yr expected)
1.65
Price/Sales (ttm)
3.44
Price/Book (mrq)
4.58
Enterprise Value/Revenue
3.93
Enterprise Value/EBITDA
18.95
Financial Highlights
Profitability and Income Statement
Profit Margin
9.97%
Return on Assets (ttm)
6.12%
Return on Equity (ttm)
14.72%
Revenue (ttm)
1.27B
Net Income Avi to Common (ttm)
126.57M
Diluted EPS (ttm)
2.46
Balance Sheet and Cash Flow
Total Cash (mrq)
195.12M
Total Debt/Equity (mrq)
92.34%
Levered Free Cash Flow (ttm)
117.23M
Research Analysis: HAE
Company Insights: HAE
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: HAE
HAE: Lowering target price to $88.00
HAEMONETICS CORP/MASS has an Investment Rating of HOLD; a target price of $88.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetHAE: Raising target price to $91.00
HAEMONETICS CORP/MASS has an Investment Rating of HOLD; a target price of $91.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetHAE: Raising target price to $88.00
HAEMONETICS CORP/MASS has an Investment Rating of HOLD; a target price of $88.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetHAE: Raising target price to $86.00
HAEMONETICS CORP/MASS has an Investment Rating of HOLD; a target price of $86.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target